Emergency Med Medical News about Pain Tapentadol

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Tapentadol immediate release for the relief of moderate-to-severe acute pain
Expert Opinion in Pharmacotherapy, 10/08/09

Hartrick CT – Tapentadol is a novel, centrally acting analgesic with two mechanisms of action: mu–opioid receptor agonism and norepinephrine reuptake inhibition. It has demonstrated broad analgesic efficacy across multiple pain models. This article reviews the clinical development of tapentadol immediate release (IR), including results from Phase II and III clinical trials that evaluated the efficacy and safety of tapentadol IR in patients with moderate–to–severe acute pain. In clinical studies in patients with moderate–to–severe acute postoperative pain, osteoarthritis pain and/or low back pain, tapentadol IR 50, 75 or 100 mg every 4 – 6 h has demonstrated analgesic efficacy similar to that observed with the mu–opioid receptor agonist oxycodone HCl IR 10 or 15 mg every 4 – 6 h. However, at doses providing comparable analgesic efficacy, tapentadol IR has been associated with significantly lower incidences of nausea and/or vomiting and constipation, and a significantly lower rate of treatment discontinuation compared with oxycodone IR.

<< Previous
Recognizing and responding to hyperglycaemic emergencies

Next >>
Improving Handoffs in the Emergency Department